

# Julio Delgado

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4864719/publications.pdf>

Version: 2024-02-01

261  
papers

10,384  
citations

57758

44  
h-index

38395

95  
g-index

271  
all docs

271  
docs citations

271  
times ranked

11452  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies. <i>Journal of the National Cancer Institute</i> , 2022, 114, 436-445.  | 6.3  | 29        |
| 2  | Balanced and unbalanced translocations in a multicentric series of 2843 patients with chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 37-43.  | 2.8  | 10        |
| 3  | Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation. <i>British Journal of Haematology</i> , 2022, 196, 146-155.   | 2.5  | 17        |
| 4  | First external validation of the FLIPI score in a single-center series of patients with follicular lymphoma. <i>Hematological Oncology</i> , 2022, 40, 297-301.   | 1.7  | 0         |
| 5  | The Prognostic Nutritional Index (PNI) is an independent predictor of overall survival in older patients with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 903-910.  | 1.3  | 4         |
| 6  | Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation. <i>Frontiers in Oncology</i> , 2022, 12, 828471.   | 2.8  | 19        |
| 7  | Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease. <i>American Journal of Hematology</i> , 2022, 97, 731-739.              | 4.1  | 6         |
| 8  | The value of anticancer drugs – a regulatory view. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 207-215.   | 27.6 | 14        |
| 9  | CD34+CD19 <sup>hi</sup> CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies. <i>Blood</i> , 2022, 140, 38-44.  | 1.4  | 20        |
| 10 | Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2022, 40, 588-595.   | 1.7  | 0         |
| 11 | ATM germline variants in a young adult with chronic lymphocytic leukemia: 8% years of genomic evolution. <i>Blood Cancer Journal</i> , 2022, 12, .  | 6.2  | 2         |
| 12 | Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party. <i>Bone Marrow Transplantation</i> , 2021, 56, 605-613. | 2.4  | 6         |
| 13 | CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies. <i>Molecular Therapy</i> , 2021, 29, 636-644.   | 8.2  | 80        |
| 14 | The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients. <i>European Journal of Haematology</i> , 2021, 106, 428-432.                        | 2.2  | 1         |
| 15 | IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics. <i>Blood</i> , 2021, 137, 2935-2946.  | 1.4  | 49        |
| 16 | Baseline correlations and prognostic impact of serum monoclonal proteins in follicular lymphoma. <i>British Journal of Haematology</i> , 2021, 193, 299-306.  | 2.5  | 5         |
| 17 | Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study. <i>Clinical Cancer Research</i> , 2021, 27, 513-521.  | 7.0  | 45        |
| 18 | A low lymphocyte-to-monocyte ratio is an independent predictor of poorer survival and higher risk of histological transformation in follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 104-111.                            | 1.3  | 9         |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy. <i>ESMO Open</i> , 2021, 6, 100031.   | 4.5  | 6         |
| 20 | EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia. <i>Oncologist</i> , 2021, 26, 242-249.   | 3.7  | 9         |
| 21 | Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. <i>Journal of Hematology and Oncology</i> , 2021, 14, 35.   | 17.0 | 51        |
| 22 | The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors. <i>ESMO Open</i> , 2021, 6, 100008.  | 4.5  | 5         |
| 23 | Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients. <i>Leukemia</i> , 2021, 35, 2325-2331.   | 7.2  | 13        |
| 24 | Age and comorbidity are determining factors in the overall and relative survival of patients with follicular lymphoma. <i>Annals of Hematology</i> , 2021, 100, 1231-1239.  | 1.8  | 3         |
| 25 | The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements. <i>ESMO Open</i> , 2021, 6, 100087. | 4.5  | 18        |
| 26 | The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer. <i>ESMO Open</i> , 2021, 6, 100074.  | 4.5  | 7         |
| 27 | The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease. <i>HemaSphere</i> , 2021, 5, e604.  | 2.7  | 3         |
| 28 | The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842V mutation. <i>ESMO Open</i> , 2021, 6, 100159.  | 4.5  | 6         |
| 29 | The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer. <i>ESMO Open</i> , 2021, 6, 100145.   | 4.5  | 29        |
| 30 | The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia. <i>HemaSphere</i> , 2021, 5, e616.  | 2.7  | 2         |
| 31 | Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia. <i>Nature Cancer</i> , 2021, 2, 853-864.  | 13.2 | 32        |
| 32 | EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma. <i>Oncologist</i> , 2021, 26, 983-987.   | 3.7  | 1         |
| 33 | Clinicobiological Characteristics and Outcomes of Patients with T-Cell Large Granular Lymphocytic Leukemia and Chronic Lymphoproliferative Disorder of Natural Killer Cells from a Single Institution. <i>Cancers</i> , 2021, 13, 3900.   | 3.7  | 12        |
| 34 | Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e985-e999.  | 0.4  | 13        |
| 35 | Is Hospital Exemption an Alternative or a Bridge to European Medicines Agency for Developing Academic Chimeric Antigen Receptor T-Cell in Europe? Our Experience with ARI-0001. <i>Human Gene Therapy</i> , 2021, 32, 1004-1007.  | 2.7  | 16        |
| 36 | Prognostic ability of five clinical risk scores in follicular lymphoma: A single-center evaluation. <i>Hematological Oncology</i> , 2021, 39, 639-649.  | 1.7  | 6         |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 37 | Serum monoclonal component in chronic lymphocytic leukemia: baseline correlations and prognostic impact. <i>Haematologica</i> , 2021, 106, 1754-1757.   | 3.5  | 2         |
| 38 | The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma. <i>HemaSphere</i> , 2021, 5, e666.       | 2.7  | 5         |
| 39 | Factors associated with the clinical outcome of patients with relapsed/refractory CD19 <sup>+</sup> acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy. , 2021, 9, e003644.                           |      | 11        |
| 40 | Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 100-114.   | 7.2  | 31        |
| 41 | Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells. <i>Oncogene</i> , 2020, 39, 1185-1197.  | 5.9  | 22        |
| 42 | The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome. <i>Clinical Cancer Research</i> , 2020, 26, 1507-1515.  | 7.0  | 13        |
| 43 | Cell Banking of HEK293T cell line for clinical-grade lentiviral particles manufacturing. <i>Translational Medicine Communications</i> , 2020, 5, .  | 1.4  | 1         |
| 44 | The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome. <i>Nature Cancer</i> , 2020, 1, 1066-1081.   | 13.2 | 51        |
| 45 | Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country. <i>Experimental Hematology and Oncology</i> , 2020, 9, 37.            | 5.0  | 9         |
| 46 | High serum levels of IL-2R, IL-6, and TNF- $\alpha$ are associated with higher tumor burden and poorer outcome of follicular lymphoma patients in the rituximab era. <i>Leukemia Research</i> , 2020, 94, 106371.         | 0.8  | 7         |
| 47 | CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report. <i>Leukemia</i> , 2020, 34, 1954-1956.   | 7.2  | 28        |
| 48 | International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 1859-1869.  | 1.4  | 86        |
| 49 | The BALL prognostic score identifies relapsed/refractory CLL patients who benefit the most from single-agent ibrutinib therapy. <i>Leukemia Research</i> , 2020, 95, 106401.  | 0.8  | 7         |
| 50 | Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC). <i>British Journal of Haematology</i> , 2020, 190, 854-863.  | 2.5  | 36        |
| 51 | Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. <i>Clinical Cancer Research</i> , 2020, 26, 2096-2103. | 7.0  | 31        |
| 52 | Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial. <i>Frontiers in Immunology</i> , 2020, 11, 482.                              | 4.8  | 77        |
| 53 | Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience. <i>Blood Cancer Journal</i> , 2020, 10, 31.                           | 6.2  | 23        |
| 54 | IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms. <i>Nature Communications</i> , 2020, 11, 3390.                            | 12.8 | 24        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 55 | COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.                             | 7.2  | 198       |
| 56 | Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. <i>Haematologica</i> , 2020, 105, 2205-2217.   | 3.5  | 47        |
| 57 | Genomic and Epigenomic Alterations in Chronic Lymphocytic Leukemia. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2020, 15, 149-177.   | 22.4 | 17        |
| 58 | Minimal spatial heterogeneity in chronic lymphocytic leukemia at diagnosis. <i>Leukemia</i> , 2020, 34, 1929-1933.  | 7.2  | 2         |
| 59 | The IGLV3-21R110 Defines a Subset of Chronic Lymphocytic Leukemia with Intermediate Epigenetic Subtype and Poor Outcome. <i>Blood</i> , 2020, 136, 43-44.   | 1.4  | 1         |
| 60 | Mutational Profile and Copy Number Alterations of Follicular Lymphoma Patients with Different Clinical Behavior. <i>Blood</i> , 2020, 136, 7-8.   | 1.4  | 0         |
| 61 | Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.  | 1.4  | 2         |
| 62 | The CLL-1100 Project: Towards Complete Genomic Characterization and Improved Prognostics for CLL. <i>Blood</i> , 2020, 136, 3-4.  | 1.4  | 2         |
| 63 | Single-Agent Ibrutinib As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice in Spain. <i>Blood</i> , 2020, 136, 32-33.   | 1.4  | 0         |
| 64 | Changes in clinical stage identify patients with <scp>CLL</scp> and different outcome within iw<scp>CLL</scp> partial response: <scp>RESONATE</scp> study. <i>British Journal of Haematology</i> , 2019, 185, 148-150.            | 2.5  | 2         |
| 65 | Immobilizing A Moving Target: CAR T Cells Hit CD22. <i>Clinical Cancer Research</i> , 2019, 25, 5188-5190.  | 7.0  | 4         |
| 66 | The U1 spliceosomal RNA is recurrently mutated in multiple cancers. <i>Nature</i> , 2019, 574, 712-716.   | 27.8 | 128       |
| 67 | Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen B cell receptors. <i>Leukemia</i> , 2019, 33, 1801-1805.   | 7.2  | 5         |
| 68 | MUTATIONAL LANDSCAPE OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT DIAGNOSIS AND AT PROGRESSION ASSESSED BY CIRCULATING TUMOR DNA ANALYSIS. <i>Hematological Oncology</i> , 2019, 37, 186-187.                                      | 1.7  | 0         |
| 69 | INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (IPS-A). <i>Hematological Oncology</i> , 2019, 37, 81-82.   | 1.7  | 1         |
| 70 | AN IMPROVED BENEFIT-RISK PROFILE OF DUVELISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WHO RECEIVED 2 OR MORE PRIOR THERAPIES. <i>Hematological Oncology</i> , 2019, 37, 213-214.              | 1.7  | 1         |
| 71 | EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL. <i>Hematological Oncology</i> , 2019, 37, 214-216.   | 1.7  | 0         |
| 72 | PATTERNS OF CHANGE IN TREATMENT, SURVIVAL, HISTOLOGICAL TRANSFORMATION, AND SECONDARY MALIGNANCIES OF FOLLICULAR LYMPHOMA OVER THE LAST 4 DECADES: A SINGLE CENTER EXPERIENCE. <i>Hematological Oncology</i> , 2019, 37, 395-397. | 1.7  | 0         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | GENOTYPING PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBCL) BY MEANS OF CIRCULATING TUMOR DNA ANALYSIS. <i>Hematological Oncology</i> , 2019, 37, 346-347.   | 1.7 | 0         |
| 74 | Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 173.      | 2.4 | 5         |
| 75 | Chimeric Antigen Receptor T Cells Targeting CD19 and Ibrutinib for Chronic Lymphocytic Leukemia. <i>HemaSphere</i> , 2019, 3, e174.   | 2.7 | 5         |
| 76 | Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. <i>Blood</i> , 2019, 133, 1205-1216.  | 1.4 | 164       |
| 77 | Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2019, 144, 2762-2773.                                  | 5.1 | 8         |
| 78 | Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CART T Cell Production at Academic Institutions. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 12, 134-144.                | 4.1 | 77        |
| 79 | Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. <i>British Journal of Haematology</i> , 2019, 184, 753-759.  | 2.5 | 49        |
| 80 | Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, 576-586.          | 3.5 | 40        |
| 81 | Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, 360-369.  | 3.5 | 42        |
| 82 | Expression of the transcribed ultraconserved region 70 and the related long non-coding RNA AC092652.2 has prognostic value in Chronic Lymphocytic Leukaemia. <i>British Journal of Haematology</i> , 2019, 184, 1045-1050.                | 2.5 | 10        |
| 83 | Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial. <i>Blood</i> , 2019, 134, 2808-2808.                                    | 1.4 | 8         |
| 84 | Effect of dose modifications on response to duvelisib in patients with relapsed/refractory (R/R) CLL/SLL in the DUO trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 7523-7523.   | 1.6 | 4         |
| 85 | Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC). <i>Blood</i> , 2019, 134, 4296-4296. | 1.4 | 2         |
| 86 | Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia. <i>Blood Cancer Journal</i> , 2018, 8, 10.   | 6.2 | 6         |
| 87 | Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. <i>Leukemia</i> , 2018, 32, 83-91.   | 7.2 | 205       |
| 88 | Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 633-642.   | 1.3 | 8         |
| 89 | Is there a role for minimal residual disease monitoring in the management of patients with hairy cell leukaemia?. <i>British Journal of Haematology</i> , 2018, 183, 127-129.   | 2.5 | 10        |
| 90 | Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia. <i>Leukemia</i> , 2018, 32, 645-653.   | 7.2 | 91        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 91  | The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2318-2326.   | 1.3  | 5         |
| 92  | The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. <i>Blood</i> , 2018, 132, 2446-2455.  | 1.4  | 261       |
| 93  | Altered patterns of global protein synthesis and translational fidelity in RPS15-mutated chronic lymphocytic leukemia. <i>Blood</i> , 2018, 132, 2375-2388.  | 1.4  | 48        |
| 94  | The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia. <i>Nature Medicine</i> , 2018, 24, 868-880.  | 30.7 | 157       |
| 95  | Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. <i>Leukemia</i> , 2018, 32, 1768-1777.   | 7.2  | 184       |
| 96  | Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study. <i>Blood</i> , 2018, 132, 1856-1856.   | 1.4  | 2         |
| 97  | A Prognostic Tool for the Identification of Patients with Early Stage Chronic Lymphocytic Leukemia at Risk of Progression. <i>Blood</i> , 2018, 132, 1834-1834.  | 1.4  | 1         |
| 98  | The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study. <i>Blood</i> , 2018, 132, 3140-3140.   | 1.4  | 2         |
| 99  | Characterization of the Long-Term Efficacy and Safety of Duvelisib Monotherapy in Patients with Relapsed/Refractory CLL/SLL on Treatment for > 2 Years across 4 Clinical Studies. <i>Blood</i> , 2018, 132, 3146-3146.   | 1.4  | 1         |
| 100 | Duvelisib inhibition of chemokines in patients with CLL (DUO study) and iNHL (DYNAMO study).. <i>Journal of Clinical Oncology</i> , 2018, 36, 12048-12048.   | 1.6  | 2         |
| 101 | Moxetumomab pasudotox in heavily pretreated patients with relapsed/refractory hairy cell leukemia: Results of a pivotal international study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7004-7004.   | 1.6  | 1         |
| 102 | The efficacy of duvelisib monotherapy following disease progression on ofatumumab monotherapy in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7533-7533.  | 1.6  | 1         |
| 103 | Targeting IRAK4 Disrupts Inflammatory Pathways and Delays Tumor Development in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 2650-2650.  | 1.4  | 0         |
| 104 | An Epigenetic Mitotic Score Tracks the Proliferative History and Capacity of CLL Samples at Diagnosis and Is Associated with Clinical Outcome. <i>Blood</i> , 2018, 132, 1842-1842.  | 1.4  | 2         |
| 105 | Tocilizumab to Prevent Infusion-Related Events in Patients with Chronic Lymphocytic Leukemia and Co-Morbidities Treated with Obinutuzumab and Chlorambucil: Results from the Randomized Phase Ib GALACTA Trial. <i>Blood</i> , 2018, 132, 4419-4419.   | 1.4  | 0         |
| 106 | Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 552-560.   | 2.4  | 35        |
| 107 | Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (<sc><i>IGHV</i></sc> mutational status and <sc>FISH</sc> cytogenetics) separates patients with different outcome and simplifies the <sc>CLL&PI</sc>. <i>American Journal of Hematology</i> , 2017, 92, 375-380. | 4.1  | 79        |
| 108 | Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2017, 18, 297-311.                 | 10.7 | 219       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Actualizaci3n de las gu3as nacionales de consenso del Grupo Espa3ol de Leucemia Linfoc3tica Cr3nica para el tratamiento y seguimiento de la leucemia linfoc3tica cr3nica. Medicina Cl3nica, 2017, 148, 381.e1-381.e9.  | 0.6 | 2         |
| 110 | Update of the Grupo Espa3ol de Leucemia Linfoc3tica Cr3nica clinical guidelines of the management of chronic lymphocytic leukemia. Medicina Cl3nica (English Edition), 2017, 148, 381.e1-381.e8.   | 0.2 | 2         |
| 111 | Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia- A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 667-675.e2. | 0.4 | 12        |
| 112 | Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with <scp>CLL</scp>: a retrospective analysis from the European Society for Blood and Marrow Transplantation (<scp>EBMT</scp>). British Journal of Haematology, 2017, 178, 521-533.                     | 2.5 | 26        |
| 113 | Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes. Stem Cell Reports, 2017, 8, 1573-1586.   | 4.8 | 73        |
| 114 | High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma. Leukemia Research, 2017, 59, 20-25.  | 0.8 | 35        |
| 115 | FcγRIIb expression in early stage chronic lymphocytic leukemia. Leukemia and Lymphoma, 2017, 58, 2642-2648.  | 1.3 | 7         |
| 116 | Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Annals of Hematology, 2017, 96, 405-410.   | 1.8 | 12        |
| 117 | Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma. Annals of Oncology, 2017, 28, 2799-2805.   | 1.2 | 22        |
| 118 | Progression-free survival shortens after each relapse in patients with follicular lymphoma treated in the rituximab era. Hematological Oncology, 2017, 35, 360-361.  | 1.7 | 4         |
| 119 | Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. British Journal of Haematology, 2017, 178, 699-708.  | 2.5 | 61        |
| 120 | Fibromyalgia as a cause of uncontrolled asthma: a case-control multicenter study. Current Medical Research and Opinion, 2017, 33, 2181-2186.   | 1.9 | 6         |
| 121 | Allergic respiratory disease (ARD), setting forth the basics: proposals of an expert consensus report. Clinical and Translational Allergy, 2017, 7, 16.  | 3.2 | 16        |
| 122 | Impact of the functional CD5 polymorphism A471V on the response of chronic lymphocytic leukaemia to conventional chemotherapy regimens. British Journal of Haematology, 2017, 177, 147-150.  | 2.5 | 8         |
| 123 | The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 1493-1505.   | 7.0 | 38        |
| 124 | Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of <i>TP53/ATM FISH</i> deletions. Oncotarget, 2017, 8, 54297-54303.  | 1.8 | 44        |
| 125 | Chronic Lymphocytic Leukemia; Pathology and Genetics. , 2017, , .  |     | 0         |
| 126 | A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia. Hematological Oncology, 2016, 34, 84-92.  | 1.7 | 26        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma. <i>European Journal of Haematology</i> , 2016, 96, 532-540.  | 2.2 | 2         |
| 128 | Advances in the treatment of chronic lymphocytic leukaemia. <i>Medicina Clínica (English Edition)</i> , 2016, 147, 447-454.   | 0.2 | 0         |
| 129 | CLL: ibrutinib and transplantation ride together. <i>Bone Marrow Transplantation</i> , 2016, 51, 769-770.   | 2.4 | 1         |
| 130 | Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. <i>Blood</i> , 2016, 127, 2122-2130.   | 1.4 | 260       |
| 131 | The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 321-329.   | 2.5 | 4         |
| 132 | <sc>CD</sc>49d (<sc>ITGA</sc>4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated <i><sc>IGHV</sc></i> status. <i>British Journal of Haematology</i> , 2016, 172, 48-55.  | 2.5 | 23        |
| 133 | Genetic evolution in chronic lymphocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 67-78.  | 1.7 | 1         |
| 134 | Present and future of personalized medicine in CLL. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 100-110.  | 1.7 | 13        |
| 135 | Clinical impact of MYD88 mutations in chronic lymphocytic leukemia. <i>Blood</i> , 2016, 127, 1611-1613.  | 1.4 | 8         |
| 136 | Maintenance therapy in chronic lymphocytic leukaemia. <i>Lancet Haematology</i> , the, 2016, 3, e399-e400.  | 4.6 | 0         |
| 137 | The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial). <i>Bone Marrow Transplantation</i> , 2016, 51, 1404-1407.                                 | 2.4 | 4         |
| 138 | A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. <i>Leukemia</i> , 2016, 30, 929-936.   | 7.2 | 200       |
| 139 | <i>MYD88</i> L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome. <i>Clinical Cancer Research</i> , 2016, 22, 2755-2764.  | 7.0 | 55        |
| 140 | Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL. <i>Blood</i> , 2016, 128, 231-231.  | 1.4 | 4         |
| 141 | CLL: A Prognostic Model Comprising Only Two Biomarkers (IGHV Mutational Status and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50<br>128, 3205-3205.  | 1.4 | 1         |
| 142 | Clinical Impact of the Quantitative Subclonal Architecture in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 2024-2024.  | 1.4 | 0         |
| 143 | A Distributed International Patient Data Registry for Hairy Cell Leukemia. <i>Blood</i> , 2016, 128, 5986-5986.   | 1.4 | 0         |
| 144 | Identification of Baseline Characteristics That Predict Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Chronic Lymphocytic Leukemia Patients - a Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.. <i>Blood</i> , 2016, 128, 522-522. | 1.4 | 0         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 145 | Center Characteristics and Procedure-Related Factors Have an Impact on Outcomes of Allogeneic Transplantation for Patients with CLL: A Retrospective Analysis from the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 4663-4663. | 1.4  | 0         |
| 146 | Clinical Impact of the Presence of a Diffuse Large B-Cell Lymphoma (DLBCL) Component in the Outcome of Untreated Patients with Follicular Lymphoma (FL). <i>Blood</i> , 2016, 128, 3043-3043.   | 1.4  | 2         |
| 147 | Tailored Approaches for Refined Prognostication in Chronic Lymphocytic Leukemia Patients with Mutated Versus Unmutated Immunoglobulin Receptors. <i>Blood</i> , 2016, 128, 3199-3199.   | 1.4  | 0         |
| 148 | Changes in Clinical Stage Identify Different Response Categories Among Patients in Iwcll PR: Analysis of CLL Patients on the Resonate Study. <i>Blood</i> , 2016, 128, 4384-4384.   | 1.4  | 0         |
| 149 | Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 668-680.   | 2.8  | 23        |
| 150 | A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2015, 10, e0143073.  | 2.5  | 24        |
| 151 | Non-coding recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , 2015, 526, 519-524.  | 27.8 | 749       |
| 152 | The biology behind PI3K inhibition in chronic lymphocytic leukaemia. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 25-36.  | 2.5  | 13        |
| 153 | Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analysis. <i>Blood Cancer Journal</i> , 2015, 5, e356-e356.                              | 6.2  | 2         |
| 154 | Survival outcomes and treatment costs for patients with double-refractory chronic lymphocytic leukaemia (<sc>DR</sc> &lt;sc>CLL</sc>). <i>British Journal of Haematology</i> , 2015, 169, 449-452.  | 2.5  | 0         |
| 155 | Mutations in the Toll-like receptor/MYD88 pathway in young (&#50 years) CLL patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S203.  | 0.4  | 0         |
| 156 | A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. <i>Leukemia</i> , 2015, 29, 598-605.   | 7.2  | 129       |
| 157 | Recurrent mutations refine prognosis in chronic lymphocytic leukemia. <i>Leukemia</i> , 2015, 29, 329-336.  | 7.2  | 253       |
| 158 | Clinical Impact of Clonal and Subclonal TP53, SF3B1, BIRC3, and ATM Mutations in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 4138-4138.   | 1.4  | 1         |
| 159 | Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study. <i>Blood</i> , 2015, 126, LBA-5-LBA-5.                  | 1.4  | 16        |
| 160 | Soluble CD30 Levels in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients. <i>American Journal of Clinical Pathology</i> , 2014, 142, A088-A088.  | 0.7  | 0         |
| 161 | Survival analysis in hematologic malignancies: recommendations for clinicians. <i>Haematologica</i> , 2014, 99, 1410-1420.  | 3.5  | 103       |
| 162 | The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy. <i>Haematologica</i> , 2014, 99, 873-880.   | 3.5  | 32        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 163 | Initial Clinico-Biological Characteristics and Follow-up Data of Elderly Patients With Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of a Series of 364 Cases. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S129-S130.  | 0.4  | 0         |
| 164 | Diagnostic and therapeutic approaches in respiratory allergy are different depending on the profile of aeroallergen sensitisation. <i>Allergologia Et Immunopathologia</i> , 2014, 42, 11-18.  | 1.7  | 8         |
| 165 | Rituximab-Based Chemoimmunotherapy Prolongs Survival of Patients With Chronic Lymphocytic Leukemia Independently of the Time of Administration. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 73-79.  | 0.4  | 4         |
| 166 | Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: Different genetic mechanisms but equivalent poorer clinical outcome. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 788-797.                          | 2.8  | 15        |
| 167 | Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. <i>Blood</i> , 2014, 123, 3790-3796.   | 1.4  | 97        |
| 168 | Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 213-223.  | 27.0 | 1,427     |
| 169 | New treatment options for chronic lymphocytic leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 823-832.  | 1.8  | 7         |
| 170 | Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption. <i>Haematologica</i> , 2014, 99, e231-e234.   | 3.5  | 33        |
| 171 | Chronic lymphocytic leukemia in young individuals revisited. <i>Haematologica</i> , 2014, 99, 4-5.   | 3.5  | 9         |
| 172 | Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model. <i>Haematologica</i> , 2014, 99, 1599-1604.  | 3.5  | 56        |
| 173 | Characterising the Burden of Chronic Lymphocytic Leukemia in Fludarabine-Ineligible Patients in Spain, Italy, and the United Kingdom (UK): A Retrospective Observational Study. <i>Blood</i> , 2014, 124, 2646-2646.   | 1.4  | 1         |
| 174 | Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATEM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2014, 124, 3331-3331.                               | 1.4  | 24        |
| 175 | Lenalidomide and Dexamethasone Combination in Patients with Chronic Lymphocytic Leukemia (CLL) Relapsing or Resistant to Treatment (LENDEX-LLC-09): A Gene Expression Profiling Study. <i>Blood</i> , 2014, 124, 4675-4675.  | 1.4  | 1         |
| 176 | Daratumumab, a Novel Anti-CD38 Monoclonal Antibody Shows Anti-Tumor Activity in CLL and hampers Leukemia-Microenvironment Interactions. <i>Blood</i> , 2014, 124, 4680-4680.   | 1.4  | 5         |
| 177 | DUO: A phase 3 trial of the PI3K-Î³ inhibitor IPI-145 versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS7122-TPS7122.  | 1.6  | 1         |
| 178 | A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS7127-TPS7127. | 1.6  | 2         |
| 179 | A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study. <i>Blood</i> , 2014, 124, 1976-1976.  | 1.4  | 2         |
| 180 | Clonal evolution in chronic lymphocytic leukemia: Analysis of correlations with IGHV mutational status, NOTCH1 mutations and clinical significance. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 920-927.   | 2.8  | 15        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 181 | NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. <i>Leukemia</i> , 2013, 27, 1100-1106.  | 7.2  | 167       |
| 182 | Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. <i>Blood</i> , 2013, 122, 3951-3959.  | 1.4  | 55        |
| 183 | Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletion. <i>British Journal of Haematology</i> , 2013, 163, 47-54.  | 2.5  | 13        |
| 184 | New Developments in Chronic Lymphocytic Leukaemia Diagnosis. <i>European Oncology and Haematology</i> , 2013, 09, 114.   | 0.0  | 0         |
| 185 | Novel Gene Mutations In Chronic Lymphocytic Leukemia: Prevalence and Clinical Implications In A Series Of 3185 Cases - Initial Results From The European Research Initiative On CLL. <i>Blood</i> , 2013, 122, 1614-1614.  | 1.4  | 0         |
| 186 | Clinical Monoclonal B Lymphocytosis (cMBL), Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Diagnostic Criteria, Features At Diagnosis and Natural History. <i>Blood</i> , 2013, 122, 5273-5273.  | 1.4  | 0         |
| 187 | Quality of life in patients with respiratory allergy is influenced by the causative allergen. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2013, 23, 309-14.  | 1.3  | 12        |
| 188 | Chronic Lymphocytic Leukemia Therapy: Beyond Chemoimmunotherapy. <i>Current Pharmaceutical Design</i> , 2012, 18, 3356-3362.   | 1.9  | 8         |
| 189 | Retreatment with purine analogs in patients with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2012, 36, 1521-1525.   | 0.8  | 5         |
| 190 | Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2012, 44, 47-52.   | 21.4 | 893       |
| 191 | Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 881-889.   | 2.8  | 57        |
| 192 | NOTCH1 mutations in chronic lymphocytic leukemia with trisomy 12. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 1064-1065.   | 2.8  | 0         |
| 193 | Degree of mucositis and duration of neutropenia are the major risk factors for early post-transplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning. <i>European Journal of Haematology</i> , 2012, 88, 46-51.   | 2.2  | 20        |
| 194 | Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results. <i>British Journal of Haematology</i> , 2012, 157, 67-74.   | 2.5  | 39        |
| 195 | Prognostic Impact of the MRD Status After Induction Treatment with Rituximab Plus Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) in Patients with Chronic Lymphocytic Leukemia Receiving Rituximab Maintenance Therapy. <i>Blood</i> , 2012, 120, 3930-3930.   | 1.4  | 0         |
| 196 | Detailed Molecular Analysis of Patients with Chronic Lymphocytic Leukemia Carrying 17p Deletions Reveals Concurrent Abnormalities with Prognostic Impact. <i>Blood</i> , 2012, 120, 4577-4577.   | 1.4  | 0         |
| 197 | 5.17 Chemoimmunotherapy Improves Survival of Patients with Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S253-S255.   | 0.4  | 0         |
| 198 | 5.40 Rituximab Maintenance in Patients with Chronic Lymphocytic Leukemia after First-Line Treatment with Rituximab plus Fludarabine, Cyclophosphamide, and Mitoxantrone: Final Results of a Multicenter Phase II Trial on Behalf of the Spanish CLL Study Group (GELLC). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S270-S272. | 0.4  | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 199 | Importance of Cyclosporine Levels in the Early Period After Reduced intensity Conditioning Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S296-S297.  | 2.0 | 0         |
| 200 | Practical Aspects of Allogeneic Hematopoietic Cell Transplantation for Patients with Poor-Risk Chronic Lymphocytic Leukemia. <i>Scientific World Journal</i> , The, 2011, 11, 161-172.  | 2.1 | 2         |
| 201 | The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphoma. <i>Leukemia</i> , 2011, 25, 551-555.  | 7.2 | 23        |
| 202 | Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. <i>Bone Marrow Transplantation</i> , 2011, 46, 52-58.  | 2.4 | 118       |
| 203 | Reduction of infection-related mortality after allogeneic PBSCT from HLA-identical siblings: longitudinal analysis from 1994 to 2008 at a single institution. <i>Bone Marrow Transplantation</i> , 2011, 46, 690-701.   | 2.4 | 18        |
| 204 | Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC). <i>Blood</i> , 2011, 118, 293-293.                               | 1.4 | 1         |
| 205 | The use of tetradecanoylphorbol acetate-stimulated peripheral blood cells enhances the prognostic value of interphase fluorescence in situ hybridization in patients with chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 327-332.  | 2.8 | 7         |
| 206 | Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. <i>Haematologica</i> , 2010, 95, 1176-1182.   | 3.5 | 63        |
| 207 | Allogeneic transplant outcomes are not affected by body mass index (BMI) in patients with haematological malignancies. <i>Annals of Hematology</i> , 2010, 89, 1141-1145.   | 1.8 | 44        |
| 208 | Comparison of Two Pretransplant Predictive Models and a Flexible HCT-CI Using Different Cut off Points to Determine Low-, Intermediate-, and High-Risk Groups: The Flexible HCT-CI Is the Best Predictor of NRM and OS in a Population of Patients Undergoing allo-RIC. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 413-420. | 2.0 | 67        |
| 209 | Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) Sustains the Response Obtained After First-Line Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM).. <i>Blood</i> , 2010, 116, 1382-1382.  | 1.4 | 1         |
| 210 | Pharmacological Inhibition of PIM Kinases In Chronic Lymphocytic Leukemia Cases with Unfavorable Prognosis Markers. <i>Blood</i> , 2010, 116, 2468-2468.  | 1.4 | 0         |
| 211 | Targeting the Apoptotic Pathway by TW-37, a Novel Bcl-2 Family Small Molecule Inhibitor, In CLL Primary Samples. <i>Blood</i> , 2010, 116, 2470-2470.   | 1.4 | 0         |
| 212 | Does reduced-intensity allogeneic transplantation confer a survival advantage to patients with poor prognosis chronic lymphocytic leukaemia? A case-control retrospective analysis. <i>Annals of Oncology</i> , 2009, 20, 2007-2012.  | 1.2 | 19        |
| 213 | Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 4578-4584.  | 1.6 | 116       |
| 214 | Beta <sub>2</sub> -microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. <i>British Journal of Haematology</i> , 2009, 145, 801-805.   | 2.5 | 41        |
| 215 | Bcl-10 protein highly correlates with the expression of phosphorylated p65 NF- $\kappa$ B in peripheral T-cell lymphomas and is associated with clinical outcome. <i>Histopathology</i> , 2009, 54, 478-485.  | 2.9 | 20        |
| 216 | Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15d $\Delta$ 12,14,PGJ2. <i>Leukemia</i> , 2009, 23, 292-304.  | 7.2 | 27        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 217 | Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2009, 44, 749-756.   | 2.4 | 51        |
| 218 | Emerging therapies for patients with advanced chronic lymphocytic leukaemia. <i>Blood Reviews</i> , 2009, 23, 217-224.   | 5.7 | 14        |
| 219 | Study of Kidney Function Impairment after Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. A Single-Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 21-29.   | 2.0 | 53        |
| 220 | Early and Late Neurological Complications after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1439-1446.   | 2.0 | 79        |
| 221 | Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen. <i>Cytotherapy</i> , 2009, 11, 356-361.   | 0.7 | 4         |
| 222 | Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?. <i>Blood</i> , 2009, 114, 2581-2588.  | 1.4 | 34        |
| 223 | The Role of In Vivo T-Cell Depletion On Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation From HLA-Identical Siblings in Patients with Follicular Lymphoma: An European Blood and Marrow Transplantation Study.. <i>Blood</i> , 2009, 114, 3375-3375. | 1.4 | 0         |
| 224 | Molecular Heterogeneity as a Basis for Rational Therapeutics in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 2348-2348.  | 1.4 | 0         |
| 225 | The Effect of In Vivo T Cell Depletion with Alemtuzumab on Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1288-1297.   | 2.0 | 53        |
| 226 | PSY21 COST-MINIMIZATION ANALYSIS OF ORALVS. INTRAVENOUS FLUDARABINE (BENEFLURÂ®) IN SPAIN. <i>Value in Health</i> , 2008, 11, A635.  | 0.3 | 0         |
| 227 | Midazolam in conjunction with local anaesthesia is superior to Entonox in providing pain relief during bone marrow aspirate and trephine biopsy. <i>Journal of Clinical Pathology</i> , 2008, 61, 1051-1054.   | 2.0 | 26        |
| 228 | Novel Epigenetic Targets in Lymphoproliferative Disorders. <i>Current Cancer Drug Targets</i> , 2008, 8, 378-391.  | 1.6 | 4         |
| 229 | Validation of Comorbidity Indexes in Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation. the Hematopoietic Cell Transplantation Comorbidity Index Is the Best Predictor of NRM and Survival.. <i>Blood</i> , 2008, 112, 3277-3277.                        | 1.4 | 2         |
| 230 | Treatment of Chronic Myeloid Leukemia with Imatinib. A Single Centre Experience. <i>Blood</i> , 2008, 112, 4289-4289.  | 1.4 | 0         |
| 231 | Targeting the Poor Mobilizing Population of Patients for An Autologous Transplantation Procedure: A Single Centre Experience. <i>Blood</i> , 2008, 112, 4136-4136.   | 1.4 | 0         |
| 232 | T-Cell Receptor Signaling Proteins, BCL10 and Phosphorylated-P65 NFKB, Are Expressed in Peripheral T-Cell Lymphomas and Associated with Clinical Outcome. <i>Blood</i> , 2008, 112, 2820-2820.   | 1.4 | 0         |
| 233 | The Use of Tetradenoylphorbol Acetate Stimulated Peripheral Blood Cells for Interphase Fluorescence In-Situ Hybridization Analysis May Enhance Its Prognostic Value for Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2008, 112, 4152-4152.                         | 1.4 | 0         |
| 234 | Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Using Oral Fludarabine as Part of the Conditioning Regimen.. <i>Blood</i> , 2007, 110, 4925-4925.   | 1.4 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 235 | Comparison of Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate in Reduced Intensity Conditioning HLA Sibling Allogeneic Stem Cell Transplantation. A Case-Match Single-Center Experience.. Blood, 2007, 110, 4994-4994. | 1.4 | 0         |
| 236 | The Effect of In Vivo T-Cell Depletion with Alemtuzumab on Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia.. Blood, 2007, 110, 3014-3014.   | 1.4 | 0         |
| 237 | Preliminary Results of the Combination Rituximab, Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) Followed by Rituximab Maintenance in Previously Untreated Chronic Lymphocytic Leukemia (CLL).. Blood, 2007, 110, 626-626.                 | 1.4 | 0         |
| 238 | The P2X7 receptor gene polymorphism 1513 Aâ€¢C has no effect on clinical prognostic markers and survival in multiple myeloma. Leukemia and Lymphoma, 2006, 47, 281-284.  | 1.3 | 20        |
| 239 | The Importance of Age, Fludarabine, and Total Body Irradiation in the Incidence and Severity of Chronic Renal Failure after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2006, 12, 75-83.           | 2.0 | 36        |
| 240 | Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood, 2006, 107, 1724-1730.  | 1.4 | 169       |
| 241 | Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia. Leukemia Research, 2006, 30, 1113-1118.  | 0.8 | 44        |
| 242 | The effect of immunoglobulinVH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer, 2006, 107, 1023-1033.   | 4.1 | 82        |
| 243 | Mcl-1 Promoter Insertions as an Independent Prognostic Factor for Treatment Free Survival in Chronic Lymphocytic Leukaemia.. Blood, 2006, 108, 4930-4930.  | 1.4 | 0         |
| 244 | Histologic Features of the Liver Biopsy Predict the Clinical Outcome for Patients with Graft-versus-Host Disease of the Liver. Biology of Blood and Marrow Transplantation, 2005, 11, 805-813.   | 2.0 | 37        |
| 245 | High D-Dimer Levels at Presentation in Patients with Venous Thrombosis Is a Marker of Poor Overall and Event Free Survival.. Blood, 2005, 106, 1625-1625.  | 1.4 | 1         |
| 246 | Results of Alemtuzumab-Based Reduced-Intensity Allogeneic Transplantation for Advanced Chronic Lymphocytic Leukemia: A BSBMT Study.. Blood, 2005, 106, 2899-2899.  | 1.4 | 0         |
| 247 | Analysis of factors affecting PBPC collection in low-weight children with malignant disorders. Cytotherapy, 2004, 6, 43-49.  | 0.7 | 13        |
| 248 | Silencing of the p18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas. Blood, 2004, 103, 2351-2357.   | 1.4 | 60        |
| 249 | The Importance of Age, Fludarabine and Total Body Irradiation in the Incidence and Severity of Chronic Renal Failure Following Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2004, 104, 2257-2257.                                   | 1.4 | 0         |
| 250 | Acquired Haemophilia: Review and Metaâ€¢Analysis Focused on Therapy and Prognostic Factors. British Journal of Haematology, 2003, 121, 21-35.  | 2.5 | 400       |
| 251 | Inappropriate analysis of reproducibility. British Journal of Haematology, 2003, 123, 745-745.   | 2.5 | 1         |
| 252 | Diagnostic Significance of CD20 and FMC7 Expression in B-Cell Disorders. American Journal of Clinical Pathology, 2003, 120, 754-759.   | 0.7 | 51        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 253 | Diagnostic Significance of CD20 and FMC7 Expression in B-Cell Disorders. American Journal of Clinical Pathology, 2003, 120, 754-759.  | 0.7 | 19        |
| 254 | Are Activation Markers (CD25, CD38 and CD103) Predictive of Sensitivity to Purine Analogues in Patients with T-cell Prolymphocytic Leukemia and other Lymphoproliferative Disorders?. Leukemia and Lymphoma, 2002, 43, 2331-2334. | 1.3 | 17        |
| 255 | Acquired hemophilia: a single-center survey with emphasis on immunotherapy and treatment-related side-effects. European Journal of Haematology, 2002, 69, 158-164.  | 2.2 | 22        |
| 256 | Cryoglobulinemia detected as a PIC/POC discrepancy of the automated complete blood count. European Journal of Haematology, 2002, 69, 65-66.   | 2.2 | 6         |
| 257 | CD56 expression in myeloperoxidase-negative FAB M5 acute myeloid leukemia. American Journal of Hematology, 2002, 69, 28-30.   | 4.1 | 11        |
| 258 | Radiation therapy and combination of cladribine, cyclophosphamide, and prednisone as treatment of Bing-Neel syndrome: Case report and review of the literature. American Journal of Hematology, 2002, 69, 127-131.                | 4.1 | 40        |
| 259 | Intrathoracic ascites. Journal of Hepatology, 2001, 34, 483.  | 3.7 | 0         |
| 260 | Relapsing polychondritis and erythema elevatum diutinum: an unusual association refractory to dapsone. Journal of Rheumatology, 2001, 28, 634-5.  | 2.0 | 8         |
| 261 | Inhibitory effects of okadaic acid on rat uterine contractile responses to different spasmogens. Fundamental and Clinical Pharmacology, 1997, 11, 47-56.  | 1.9 | 4         |